Zolpidem use and risk of suicide: A systematic review and
meta-analysis

J 2022

Zolpidem use and risk of suicide: A systematic review and meta-analysis

KHAN, Hiba, Aakriti GARG, Yasmeen YASMEEN, Nidhi B. AGARWAL, Deepak Kumar YADAV et. al.

Basic information

Original name

Zolpidem use and risk of suicide: A systematic review and meta-analysis

Authors

KHAN, Hiba, Aakriti GARG, Yasmeen YASMEEN, Nidhi B. AGARWAL, Deepak Kumar YADAV, Mohd ASHIF KHAN and Mohammad Salman HUSSAIN (356 India, belonging to the institution)

Edition

Psychiatry Research, CLARE, ELSEVIER IRELAND LTD, 2022, 0165-1781

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30215 Psychiatry

Country of publisher

Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 11.300

RIV identification code

RIV/00216224:14110/22:00126537

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.psychres.2022.114777

UT WoS

000862817400004

Keywords in English

Death; Epidemiology; Insomnia; Systematic review; Meta-analysis; Suicide; Zolpidem

Abstract

V originále

Introduction Zolpidem is one of the most commonly prescribed nonbenzodiazepine hypnotic drugs for insomnia. Published epidemiological studies linked zolpidem with the risk of suicide. However, to date, no meta-analysis investigated this association. Hence, we systematically reviewed and meta-analysed the current evidence from real-world studies reporting the risk of suicide with the use of zolpidem. Methods Medline (Ovid), Embase (Ovid), and PsycINFO databases were searched from inception till June 2021 for real-world evidence studies reporting the risk of suicide with the use of zolpidem. The quality assessment of included studies was assessed using the New-Castle Ottawa Scale (NOS). Random-effect meta-analysis was performed using a generic inverse variance method. Results This meta-analysis was based on four studies with 344,753 participants, of which 42,279 were zolpidem users. The methodological quality of all the included studies was of high quality. A significantly increased risk of suicide or suicide attempt was found in zolpidem users compared to non-users, with a pooled relative risk of 1.88 (95% CI: 1.54 – 2.30). Furthermore, an increased risk of suicidal death was observed in zolpidem users compared to non-users, with a pooled relative risk of 1.82 (95% CI: 1.43 – 2.30). Dose-response analysis also revealed a significantly increased risk of suicide in patients receiving ≥ 180cDDD (cumulative defined daily doses) of zolpidem (124 times), followed by 90–179cDDD (113 times) and <90cDDD (93 times) of zolpidem compared to non-users. Conclusion In conclusion, zolpidem use was associated with an increased risk of suicide or suicide attempt and suicidal death. Therefore, careful prescribing practices must be followed by considering the risk-benefit profile.

Links

EF18_053/0016952, research and development project

Name: Postdoc2MUNI

Citovat

KHAN, Hiba, Aakriti GARG, Yasmeen YASMEEN, Nidhi B. AGARWAL, Deepak Kumar YADAV, Mohd ASHIF KHAN and Mohammad Salman HUSSAIN. Zolpidem use and risk of suicide: A systematic review and meta-analysis. Psychiatry Research. CLARE: ELSEVIER IRELAND LTD, 2022, vol. 316, October 2022, p. 1-8. ISSN 0165-1781. Available from: https://dx.doi.org/10.1016/j.psychres.2022.114777.

@article{2213957,
   author = {Khan, Hiba and Garg, Aakriti and Yasmeen, Yasmeen and Agarwal, Nidhi B. and Yadav, Deepak Kumar and Ashif Khan, Mohd and Hussain, Mohammad Salman},
   article_location = {CLARE},
   article_number = {October 2022},
   doi = {http://dx.doi.org/10.1016/j.psychres.2022.114777},
   keywords = {Death; Epidemiology; Insomnia; Systematic review; Meta-analysis; Suicide; Zolpidem},
   language = {eng},
   issn = {0165-1781},
   journal = {Psychiatry Research},
   title = {Zolpidem use and risk of suicide: A systematic review and meta-analysis},
   url = {https://www.sciencedirect.com/science/article/pii/S0165178122003717},
   volume = {316},
   year = {2022}
}

TY  - JOUR
ID  - 2213957
AU  - Khan, Hiba - Garg, Aakriti - Yasmeen, Yasmeen - Agarwal, Nidhi B. - Yadav, Deepak Kumar - Ashif Khan, Mohd - Hussain, Mohammad Salman
PY  - 2022
TI  - Zolpidem use and risk of suicide: A systematic review and meta-analysis
JF  - Psychiatry Research
VL  - 316
IS  - October 2022
SP  - 1-8
EP  - 1-8
PB  - ELSEVIER IRELAND LTD
SN  - 01651781
KW  - Death
KW  - Epidemiology
KW  - Insomnia
KW  - Systematic review
KW  - Meta-analysis
KW  - Suicide
KW  - Zolpidem
UR  - https://www.sciencedirect.com/science/article/pii/S0165178122003717
N2  - Introduction Zolpidem is one of the most commonly prescribed nonbenzodiazepine hypnotic drugs for insomnia. Published epidemiological studies linked zolpidem with the risk of suicide. However, to date, no meta-analysis investigated this association. Hence, we systematically reviewed and meta-analysed the current evidence from real-world studies reporting the risk of suicide with the use of zolpidem. Methods Medline (Ovid), Embase (Ovid), and PsycINFO databases were searched from inception till June 2021 for real-world evidence studies reporting the risk of suicide with the use of zolpidem. The quality assessment of included studies was assessed using the New-Castle Ottawa Scale (NOS). Random-effect meta-analysis was performed using a generic inverse variance method. Results This meta-analysis was based on four studies with 344,753 participants, of which 42,279 were zolpidem users. The methodological quality of all the included studies was of high quality. A significantly increased risk of suicide or suicide attempt was found in zolpidem users compared to non-users, with a pooled relative risk of 1.88 (95% CI: 1.54 – 2.30). Furthermore, an increased risk of suicidal death was observed in zolpidem users compared to non-users, with a pooled relative risk of 1.82 (95% CI: 1.43 – 2.30). Dose-response analysis also revealed a significantly increased risk of suicide in patients receiving ≥ 180cDDD (cumulative defined daily doses) of zolpidem (124 times), followed by 90–179cDDD (113 times) and <90cDDD (93 times) of zolpidem compared to non-users. Conclusion In conclusion, zolpidem use was associated with an increased risk of suicide or suicide attempt and suicidal death. Therefore, careful prescribing practices must be followed by considering the risk-benefit profile.
ER  -

KHAN, Hiba, Aakriti GARG, Yasmeen YASMEEN, Nidhi B. AGARWAL, Deepak Kumar YADAV, Mohd ASHIF KHAN and Mohammad Salman HUSSAIN. Zolpidem use and risk of suicide: A systematic review and meta-analysis. \textit{Psychiatry Research}. CLARE: ELSEVIER IRELAND LTD, 2022, vol.~316, October 2022, p.~1-8. ISSN~0165-1781. Available from: https://dx.doi.org/10.1016/j.psychres.2022.114777.

Detailed Information on Publication Record